Tapinarof Eczema Trials Across Skin Types: What the Subgroup Analysis Shows

Dr. Arsy Editorial Team · November 9, 2026

Eczema trials need diverse participation because inflammation and redness can appear differently across skin tones. A subgroup analysis of the ADORING 1 and 2 phase 3 trials examined tapinarof cream outcomes by reported race and Fitzpatrick skin type.^[5][15]

A diverse trial population

ADORING 1 and 2 randomized 407 and 406 adults and children. More than half of participants had Fitzpatrick skin types IV–VI. At week eight, validated IGA success was more frequent with tapinarof than vehicle across Asian, Black or African American, and White groups, and across Fitzpatrick I–III and IV–VI categories.^[5]

Why subgroup consistency is reassuring but not definitive

The trials were not necessarily powered to prove equality of treatment effects between every racial subgroup. Race is a social and demographic category, while Fitzpatrick type was designed around tanning and burning response rather than eczema visibility. Neither perfectly captures the diversity of skin color, ancestry or lived experience.

Do not transfer one product’s results

The study tested tapinarof cream 1% once daily against its vehicle under a defined protocol. Its response rates cannot be assigned to a different moisturizer, prescription cream or over-the-counter product. It also does not mean every person within a group will respond similarly.

What better representation improves

• Confidence that efficacy signals are not limited to lighter skin
• Detection of adverse effects across diverse participants
• Evaluation of severity tools when erythema is less visible
• More relevant counseling for families historically underrepresented

Treatment choice should consider age, disease extent, body location, prior therapy, safety and current regulatory labeling. Subgroup analyses support inclusivity; they do not replace individualized care.^{[9][10][11][19][20]}

Product context

Dr. Arsy Moisturizer #003 is a cosmetic moisturizer for dry, sensitive and eczema-prone skin. It was not evaluated in the research above and is not a substitute for medical assessment or prescription care. Ask a pediatric clinician before using a specific product on a baby.

Related pediatric eczema research

• Does Childhood Eczema Lower Test Scores? A 3,641-Child Study Challenges Assumptions
• Pediatric Eczema Treatment Across Skin Colors: What the PEDISTAD Registry Observed
• Eczema and Child Growth: What a 1,329-Child PEDISTAD Analysis Can—and Cannot—Say
• Dupilumab, Skin Proteins and the Microbiome: What TREATKids Added Beyond EASI
• Related pediatric eczema guide
• Related pediatric eczema guide

Research and clinical references

1. Childhood atopic dermatitis and standardized testing: US birth cohort.
2. PEDISTAD systemic treatment outcomes by skin color.
3. PEDISTAD growth assessment in children under 12.
4. TREATKids clinical and molecular outcomes with dupilumab.
5. Tapinarof efficacy by race and Fitzpatrick skin type.
6. Atopic dermatitis and academic performance in Denmark and England.
7. Atopic dermatitis, sleep and cognition in US adults.
8. Eczema and educational attainment: systematic review.
9. Pediatric atopic dermatitis guideline.
10. AAP skin-directed management clinical report.
11. AAAAI/ACAAI atopic dermatitis guideline.
12. Dupilumab in children 6 months to younger than 6 years.
13. Dupilumab in children 6 to 11 years with severe atopic dermatitis.
14. Dupilumab in adolescents with atopic dermatitis.
15. Tapinarof ADORING phase 3 trials.
16. Long-term topical therapy in pediatric atopic dermatitis: ROAD study.
17. Atopic dermatitis and child height: systematic review.
18. Growth and nutritional status in children with atopic dermatitis.
19. Atopic dermatitis in skin of color: clinical considerations.
20. Racial and ethnic representation in atopic dermatitis trials.
21. Core outcome instruments for atopic eczema.
22. EASI validation across skin types.
23. Patient-Oriented Eczema Measure validation in children.
24. Atopic dermatitis quality-of-life burden in children and families.

Educational information only; not medical advice. Cited researchers and organizations do not endorse Dr. Arsy products.